title: Epidemiology of cutaneous melanoma in Sweden-Stage-specific survival and rate of recurrence.
abstract: Cutaneous malignant melanoma (CMM) incidence is increasing globally, making a thorough understanding of the disease and its outcomes essential for optimizing care even more urgent. In this population-based, retrospective study, we investigated stage-specific survival and recurrence/progression rates of CMM among patients diagnosed in Stockholm County Council during 2005-2012, before the wide introduction of targeted therapy. A total of 3,554 CMM patients from the Stockholm Melanoma Register were included. Information on comorbidities, progression, death, and treatments was obtained from nationwide registers and hospital electronic medical records. Unadjusted 5-year survival varied from 91.4% for stage I to 24.6% for stage IV patients. Stage, age and gender were predictors of survival, with gender an independent predictor of survival for stages IA and IIA. 74.6% of patients remained recurrence/progression-free during follow-up, with 5-year recurrence/progression-free survival rates varying from 85.3% to 12.9% among stages I and IV patients, respectively. In addition to stage, male gender, and age, circulatory system comorbidities increased the risk for recurrence/progression. No statistically significant differences in progression rate for operated and non-operated patients could be detected, possibly due to high rate (98.9%) of surgery. Our estimates of survival and recurrence rates are consistent with historical and global expectations and can serve as a baseline to gauge population-level improvements with use of novel melanoma treatments.
authors: Pygargus AB/IMS Health Sweden AB, Pyramidvägen 7, Solna, Sweden 169 56.
authors: Julia
authors: J
authors: Rockberg
authors: Amgen Inc, Uxbridge Business Park, Uxbridge, UK UB8 1DH.
authors: Justyna M
authors: JM
authors: Amelio
authors: Amgen Inc, Uxbridge Business Park, Uxbridge, UK UB8 1DH.
authors: Aliki
authors: A
authors: Taylor
authors: Pygargus AB/IMS Health Sweden AB, Pyramidvägen 7, Solna, Sweden 169 56.
authors: Leif
authors: L
authors: Jörgensen
authors: Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, Solna, Sweden 171 76.
authors: Peter
authors: P
authors: Ragnhammar
authors: Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, Solna, Sweden 171 76. johan.hansson@ki.se.
authors: Johan
authors: J
authors: Hansson
mesh_terms: D000328:Adult; D000368:Aged; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008545:Melanoma / Q000453:epidemiology / Q000401:mortality* / Q000473:pathology*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011159:Population Surveillance; D011379:Prognosis; D016016:Proportional Hazards Models; D012042:Registries; D012189:Retrospective Studies; D012878:Skin Neoplasms; D015996:Survival Rate; D013548:Sweden / Q000453:epidemiology; D000096142:Cutaneous Malignant Melanoma
keywords: melanoma; progression; recurrence; stage at diagnosis; survival